Karyopharm Therapeutics - Cancer Play mit voller Pipeline und günstiger Bewertung (Seite 9)
eröffnet am 02.12.20 16:57:34 von
neuester Beitrag 06.02.24 17:18:41 von
neuester Beitrag 06.02.24 17:18:41 von
Beiträge: 96
ID: 1.335.414
ID: 1.335.414
Aufrufe heute: 0
Gesamt: 10.610
Gesamt: 10.610
Aktive User: 0
ISIN: US48576U1060 · WKN: A1W77U · Symbol: KPTI
1,1300
USD
+4,63 %
+0,0500 USD
Letzter Kurs 04.05.24 Nasdaq
Werte aus der Branche Biotechnologie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 41,21 | +28,74 | |
| 8,7200 | +28,42 | |
| 10,155 | +21,04 | |
| 8,1400 | +20,41 | |
| 8,0200 | +19,35 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 1,9999 | -19,36 | |
| 3,5200 | -21,43 | |
| 3,5000 | -26,24 | |
| 1,7000 | -49,40 | |
| 125,00 | -95,83 |
Beitrag zu dieser Diskussion schreiben
Feedback
Karyopharm Announces FDA Approval of XPOVIO® (Selinexor) as a Treatment for Patients with Multiple Myeloma After At Least One Prior Therapy
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:…
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:…
Stock halted pending news
Antwort auf Beitrag Nr.: 66.100.684 von bcgk am 17.12.20 10:56:19Quelle: https://www.cnbc.com/2020/11/27/analysts-say-bet-on-stocks-l…
Antwort auf Beitrag Nr.: 66.087.463 von bcgk am 16.12.20 14:23:59Karyopharm Therapeutics: BUY
Top healthcare analyst Edward White, of H.C. Wainwright, takes a bullish stance on Karyopharm Therapeutics, which focuses on the development of therapies for patients with cancer and other serious diseases. He reiterated a Buy rating on November 25 as well as a $41 price target, suggesting 178% upside potential.
The call came in response to KPTI’s announcement that the ongoing Phase 3 SIENDO study passed its interim futility analysis, and the Data and Safety Monitoring Board (DSMB) suggested the study should proceed as planned without any modifications.
SIENDO is a Phase 3 study evaluating the efficacy and safety of Xpovio (the company’s oral selective inhibitor designed to bind and inhibit XPO1, a nuclear export protein) as a frontline maintenance therapy in patients with advanced or recurrent endometrial cancer. Top line data from the study will likely be reported in 2H21.
White points out that the FDA has already approved the therapy as a treatment for relapsed or refractory (r/r) multiple myeloma (MM) and r/r diffuse large B-cell lymphoma (DLBCL).
The drug’s potential extends beyond these indications, with the analyst highlighting that last week, “positive Phase 3 SEAL data were presented at the Connective Tissue Oncology Society 2020 Annual Meeting (CTOS 2020). It was previously reported that the SEAL study, evaluating single agent Xpovio in patients with advanced unresectable dedifferentiated liposarcoma, met its primary endpoint of a statistically significant increase in median progression-free survival.”
Bearing this in mind, White estimates Xpovio sales in dedifferentiated liposarcoma could reach $3 million in 2022, increasing to $26 million in 2026. When considering the therapy’s potential in solid tumors other than dedifferentiated liposarcoma, the analyst expects a launch in 2023 with revenues of $39.9 million that year, growing to $199.5 million in 2026.
With the analyst boasting a 34.2% average return per rating, White is ranked #113 on TipRanks’ list of best-performing analysts.
Top healthcare analyst Edward White, of H.C. Wainwright, takes a bullish stance on Karyopharm Therapeutics, which focuses on the development of therapies for patients with cancer and other serious diseases. He reiterated a Buy rating on November 25 as well as a $41 price target, suggesting 178% upside potential.
The call came in response to KPTI’s announcement that the ongoing Phase 3 SIENDO study passed its interim futility analysis, and the Data and Safety Monitoring Board (DSMB) suggested the study should proceed as planned without any modifications.
SIENDO is a Phase 3 study evaluating the efficacy and safety of Xpovio (the company’s oral selective inhibitor designed to bind and inhibit XPO1, a nuclear export protein) as a frontline maintenance therapy in patients with advanced or recurrent endometrial cancer. Top line data from the study will likely be reported in 2H21.
White points out that the FDA has already approved the therapy as a treatment for relapsed or refractory (r/r) multiple myeloma (MM) and r/r diffuse large B-cell lymphoma (DLBCL).
The drug’s potential extends beyond these indications, with the analyst highlighting that last week, “positive Phase 3 SEAL data were presented at the Connective Tissue Oncology Society 2020 Annual Meeting (CTOS 2020). It was previously reported that the SEAL study, evaluating single agent Xpovio in patients with advanced unresectable dedifferentiated liposarcoma, met its primary endpoint of a statistically significant increase in median progression-free survival.”
Bearing this in mind, White estimates Xpovio sales in dedifferentiated liposarcoma could reach $3 million in 2022, increasing to $26 million in 2026. When considering the therapy’s potential in solid tumors other than dedifferentiated liposarcoma, the analyst expects a launch in 2023 with revenues of $39.9 million that year, growing to $199.5 million in 2026.
With the analyst boasting a 34.2% average return per rating, White is ranked #113 on TipRanks’ list of best-performing analysts.
Trading Spotlight
Antwort auf Beitrag Nr.: 66.079.708 von bcgk am 15.12.20 22:10:25Nochmal die letzten PR des Unternehmens aus November 2020:
Karyopharm Announces Phase 3 SEAL Study Meets Primary Endpoint with Significant Increase in Progression-Free Survival in Patients with Unresectable Dedifferentiated Liposarcoma
https://investors.karyopharm.com/2020-11-02-Karyopharm-Annou…
Phase 3 SEAL Study Meets Primary Endpoint with Significant Increase in Progression-Free Survival in Patients with Unresectable Dedifferentiated Liposarcoma
Third Quarter 2020 XPOVIO Net Product Sales of $21.3 Million; Quarterly Sales Continue Strong Momentum, Increasing Approximately 15% Compared to the Second Quarter of 2020
XPOVIO Supplemental New Drug Application Seeking Approval for Patients with Multiple Myeloma After At Least One Prior Line of Therapy Assigned a Target PDUFA Action Date of March 19, 2021
https://investors.karyopharm.com/2020-11-02-Karyopharm-Repor…
Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that following a pre-specified interim futility analysis for the ongoing Phase 3 SIENDO study, the Data and Safety Monitoring Board (DSMB) has recommended that the study should continue, as previously planned, without the need for adding additional patients to the trial or amending the study protocol.
https://investors.karyopharm.com/2020-11-25-Karyopharm-Annou…
Karyopharm Announces Phase 3 SEAL Study Meets Primary Endpoint with Significant Increase in Progression-Free Survival in Patients with Unresectable Dedifferentiated Liposarcoma
https://investors.karyopharm.com/2020-11-02-Karyopharm-Annou…
Phase 3 SEAL Study Meets Primary Endpoint with Significant Increase in Progression-Free Survival in Patients with Unresectable Dedifferentiated Liposarcoma
Third Quarter 2020 XPOVIO Net Product Sales of $21.3 Million; Quarterly Sales Continue Strong Momentum, Increasing Approximately 15% Compared to the Second Quarter of 2020
XPOVIO Supplemental New Drug Application Seeking Approval for Patients with Multiple Myeloma After At Least One Prior Line of Therapy Assigned a Target PDUFA Action Date of March 19, 2021
https://investors.karyopharm.com/2020-11-02-Karyopharm-Repor…
Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that following a pre-specified interim futility analysis for the ongoing Phase 3 SIENDO study, the Data and Safety Monitoring Board (DSMB) has recommended that the study should continue, as previously planned, without the need for adding additional patients to the trial or amending the study protocol.
https://investors.karyopharm.com/2020-11-25-Karyopharm-Annou…
Antwort auf Beitrag Nr.: 65.932.176 von StellaVella am 03.12.20 10:32:55Leider ist das hier bislang eine einzige Enttäuschung. Die letzten Tage gab es auch einige Insiderverkäufe. So recht kann ich mir hier keinen Reim darauf machen. Boston Studie sieht sehr gut aus, PDUFA keine 90 Tage weg....komisch.
Antwort auf Beitrag Nr.: 65.932.176 von StellaVella am 03.12.20 10:32:55Ist ein interessanter Titel, den ich auch schon länger im Blick habe... Chart sieht, wie hier schon angemerkt, sehr schön aus. Wichtig ist vor allem die label-Erweiterung für second-line MM.
Mir persönlich ist der Space zu crowded, daher konnte/kann ich mich bisher nicht durchringen.
Kann aber zweifellos min. 2x höher bewertet sein, und ist auch ein nicht uninteressantes Übernahmeziel.
Mir persönlich ist der Space zu crowded, daher konnte/kann ich mich bisher nicht durchringen.
Kann aber zweifellos min. 2x höher bewertet sein, und ist auch ein nicht uninteressantes Übernahmeziel.
Mal sehen, wo wir nächstes Jahr stehen.
Danke.
Danke.
Antwort auf Beitrag Nr.: 65.923.560 von bcgk am 02.12.20 16:57:34Danke Dir für den Tipp. Sieht tatsächlich sehr vielversprechend aus. Werde mich auch um eine erste Position bemühen 😉
Durchsuchen
